The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells

被引:123
作者
Maggio, SC
Rosato, RR
Kramer, LB
Dai, Y
Rahmani, M
Paik, DS
Czarnik, AC
Payne, SG
Spiegel, S
Grant, S
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol, Richmond, VA 23298 USA
关键词
D O I
10.1158/0008-5472.CAN-03-2631
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interactions between the novel benzamide histone deacetylase (HDAC) inhibitor MS-275 and fludarabine were examined in lymphoid and myeloid human leukemia cells in relation to mitochondrial injury, signal transduction events, and apoptosis. Prior exposure of Jurkat lymphoblastic leukemia cells to a marginally toxic concentration of MS-275 (e.g., 500 nm) for 24 h sharply increased mitochondrial injury, caspase activation, and apoptosis in response to a minimally toxic concentration of fludarabine (500 rim), resulting in highly synergistic antileukemic interactions and loss of clonogenic survival. Simultaneous exposure to MS-275 and fludarabine also led to synergistic effects, but these were not as pronounced as observed with sequential treatment. Similar interactions were noted in the case of (a) other human leukemia cell lines (e.g., U937, CCRF-CEM); (b) other HDAC inhibitors (e.g., sodium butyrate); and (c) other nucleoside analogues (e.g., 1-beta-D-arabinofuranosylcytosine, gemcitabine). Potentiation of fludarabine lethality by MS-275 was associated with acetylation of histories H3 and H4, down-regulation of the antiapoptotic proteins XIAP and Mcl-1, enhanced cytosolic release of proapoptotic mitochondrial proteins (e.g., cytochrome c, Smac/DIABLO, and apoptosis-inducing factor), and caspase activation. It was also accompanied by the caspase-dependent down-regulation of p27(KIP1), cyclins A, E, and D-1, and cleavage and diminished phosphorylation of retinoblastoma protein. However, increased lethality of the combination was not associated with enhanced fludarabine triphosphate formation or DNA incorporation and occurred despite a slight reduction in the S-phase fraction. Prior exposure to MS-275 attenuated fludarabine-mediated activation of MEK1/2, extracellular signal-regulated kinase, and Akt, and enhanced c-Jun NH2-terminal kinase phosphorylation; furthermore, inducible expression of constitutively active MEK1/2 or Akt significantly diminished MS-275/fludarabine-induced lethality. Combined exposure of cells to MS-275 and fludarabine was associated with a significant increase in generation of reactive oxygen species; moreover, both the increase in reactive oxygen species and apoptosis were largely attenuated by coadministration of the free radical scavenger L-N-acetylcysteine. Finally, prior administration of MS-275 markedly potentiated fludarabine-mediated generation of the proapoptotic lipid second messenger ceramide. Taken together, these flndings indicate that the HDAC inhibitor MS-275 induces multiple perturbations in signal transduction, survival, and cell cycle regulatory pathways that lower the threshold for fludarabine-mediated mitochondrial injury and apoptosis in human leukemia cells. They also provide insights into possible mechanisms by which novel, clinically relevant HDAC inhibitors might be used to enhance the antileukemic activity of established nucleoside analogues such as fludarabine.
引用
收藏
页码:2590 / 2600
页数:11
相关论文
共 79 条
[1]   Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK [J].
Allan, LA ;
Morrice, N ;
Brady, S ;
Magee, G ;
Pathak, S ;
Clarke, PR .
NATURE CELL BIOLOGY, 2003, 5 (07) :647-U45
[2]  
Backway KL, 1997, CANCER RES, V57, P2446
[3]   Stress signals for apoptosis: ceramide and c-Jun kinase [J].
Basu, S ;
Kolesnick, R .
ONCOGENE, 1998, 17 (25) :3277-3285
[4]   Immediate-early gene induction by the stresses anisomycin and arsenite in human osteosarcoma cells involves MAPK cascade signaling to Elk-1, CREB and SRF [J].
Bébien, M ;
Salinas, S ;
Becamel, C ;
Richard, W ;
Linares, L ;
Hipskind, RA .
ONCOGENE, 2003, 22 (12) :1836-1847
[5]  
BHATIA U, 1995, CELL GROWTH DIFFER, V6, P937
[6]   Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells [J].
Biswal, SS ;
Datta, K ;
Acquaah-Mensah, GK ;
Kehrer, JP .
TOXICOLOGY, 2000, 154 (1-3) :45-53
[7]   The role of MAPK pathways in the action of chemotherapeutic drugs [J].
Boldt, S ;
Weidle, UH ;
Kolch, W .
CARCINOGENESIS, 2002, 23 (11) :1831-1838
[8]   Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms [J].
Bonni, A ;
Brunet, A ;
West, AE ;
Datta, SR ;
Takasu, MA ;
Greenberg, ME .
SCIENCE, 1999, 286 (5443) :1358-1362
[9]   BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability [J].
Brimmell, M ;
Mendiola, R ;
Mangion, J ;
Packham, G .
ONCOGENE, 1998, 16 (14) :1803-1812
[10]  
BROCKMAN RW, 1980, CANCER RES, V40, P3610